Harvard Bioscience, Inc. (NASDAQ:HBIO) Short Interest Up 22.8% in December

Harvard Bioscience, Inc. (NASDAQ:HBIO) was the recipient of a significant increase in short interest in December. As of December 15th, there was short interest totaling 586,355 shares, an increase of 22.8% from the November 30th total of 477,324 shares. Approximately 1.5% of the shares of the stock are short sold. Based on an average daily volume of 679,967 shares, the short-interest ratio is presently 0.9 days. Based on an average daily volume of 679,967 shares, the short-interest ratio is presently 0.9 days. Approximately 1.5% of the shares of the stock are short sold.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Benchmark dropped their price target on Harvard Bioscience from $3.00 to $2.00 and set a “speculative buy” rating for the company in a research note on Wednesday, September 10th. Wall Street Zen raised Harvard Bioscience from a “hold” rating to a “buy” rating in a report on Monday, November 17th. Zacks Research upgraded Harvard Bioscience to a “hold” rating in a research report on Thursday, December 11th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Harvard Bioscience in a research report on Monday. One equities research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $2.00.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Nuveen LLC bought a new stake in shares of Harvard Bioscience in the 1st quarter worth about $79,000. Williams & Novak LLC grew its holdings in Harvard Bioscience by 37.0% during the 2nd quarter. Williams & Novak LLC now owns 106,570 shares of the medical instruments supplier’s stock valued at $47,000 after purchasing an additional 28,800 shares during the last quarter. Deutsche Bank AG raised its position in Harvard Bioscience by 221.1% in the 1st quarter. Deutsche Bank AG now owns 75,985 shares of the medical instruments supplier’s stock worth $43,000 after purchasing an additional 52,319 shares during the period. AMH Equity Ltd raised its position in Harvard Bioscience by 3.6% in the 2nd quarter. AMH Equity Ltd now owns 3,508,703 shares of the medical instruments supplier’s stock worth $1,557,000 after purchasing an additional 121,348 shares during the period. Finally, Landscape Capital Management L.L.C. bought a new stake in Harvard Bioscience in the first quarter worth about $33,000. Institutional investors own 80.87% of the company’s stock.

Harvard Bioscience Price Performance

Shares of Harvard Bioscience stock traded up $0.01 on Wednesday, reaching $0.67. The company had a trading volume of 268,501 shares, compared to its average volume of 4,919,010. The firm has a market cap of $29.82 million, a price-to-earnings ratio of -0.55 and a beta of 1.53. The firm’s 50-day moving average price is $0.65 and its two-hundred day moving average price is $0.53. Harvard Bioscience has a 1 year low of $0.28 and a 1 year high of $2.28.

About Harvard Bioscience

Harvard Bioscience, Inc develops, manufactures and distributes life science research instruments and consumables used by academic, biopharmaceutical and government laboratories worldwide. The company’s product portfolio spans cellular physiology, microfluidics, electrophysiology and lab automation, providing tools that enable researchers to study everything from cell behavior and organ function to drug delivery and tissue mechanics.

Through its operating units—most notably Harvard Apparatus, BTX, Radnoti and Warner Instruments—Harvard Bioscience offers a diverse range of scientific equipment including precision pumps, stereotaxic instruments, electroporation and gene delivery systems, perfusion systems and microinjection tools.